CHARMD

Comprehensive Herpesviruses Antiviral drug Resistance Mutation Database


    • TOP

    D981del2

    Antiviral assays:

    Antiviral EC50 ratio Phenotype Strain Source Marker Assay Reference
    Cidofovir 3.20 Intermediate level resistance Clinical Isolate Details Emergence of letermovir resistance in a lung transplant recipient with ganciclovir-resistant cytomegalovirus infection. (Dec 2018)
    Cidofovir 3.20 Intermediate level resistance Clinical Isolate Details A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials. (Feb 2026)
    Cidofovir 3.70 Intermediate level resistance Clinical Isolate Details Drug Resistance Mutations and Associated Phenotypes Detected in Clinical Trials of Maribavir for Treatment of Cytomegalovirus Infection. (Sep 2022)
    Foscarnet 2.70 Low level resistance Clinical Isolate Details Emergence of letermovir resistance in a lung transplant recipient with ganciclovir-resistant cytomegalovirus infection. (Dec 2018)
    Foscarnet 3.00 Intermediate level resistance Clinical Isolate Details A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials. (Feb 2026)
    Foscarnet 3.10 Intermediate level resistance Clinical Isolate Details Drug Resistance Mutations and Associated Phenotypes Detected in Clinical Trials of Maribavir for Treatment of Cytomegalovirus Infection. (Sep 2022)
    Ganciclovir 7.00 High level resistance Clinical Isolate Details Emergence of letermovir resistance in a lung transplant recipient with ganciclovir-resistant cytomegalovirus infection. (Dec 2018)
    Ganciclovir 7.50 High level resistance Clinical Isolate Details A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials. (Feb 2026)
    Ganciclovir 6.20 High level resistance Clinical Isolate Details Drug Resistance Mutations and Associated Phenotypes Detected in Clinical Trials of Maribavir for Treatment of Cytomegalovirus Infection. (Sep 2022)

    Tilloy et al., 2024
    Interdeposit Digital Number: IDDN.FR.001.420004.000.S.X.2024.000.31230